209 related articles for article (PubMed ID: 22911111)
1. Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer.
Zhang L; Poh CF; Williams M; Laronde DM; Berean K; Gardner PJ; Jiang H; Wu L; Lee JJ; Rosin MP
Cancer Prev Res (Phila); 2012 Sep; 5(9):1081-9. PubMed ID: 22911111
[TBL] [Abstract][Full Text] [Related]
2. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia.
Rosin MP; Cheng X; Poh C; Lam WL; Huang Y; Lovas J; Berean K; Epstein JB; Priddy R; Le ND; Zhang L
Clin Cancer Res; 2000 Feb; 6(2):357-62. PubMed ID: 10690511
[TBL] [Abstract][Full Text] [Related]
3. Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer.
Cavenee WK
Cancer Prev Res (Phila); 2012 Sep; 5(9):1073-4. PubMed ID: 22911109
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
William WN; Papadimitrakopoulou V; Lee JJ; Mao L; Cohen EE; Lin HY; Gillenwater AM; Martin JW; Lingen MW; Boyle JO; Shin DM; Vigneswaran N; Shinn N; Heymach JV; Wistuba II; Tang X; Kim ES; Saintigny P; Blair EA; Meiller T; Gutkind JS; Myers J; El-Naggar A; Lippman SM
JAMA Oncol; 2016 Feb; 2(2):209-16. PubMed ID: 26540028
[TBL] [Abstract][Full Text] [Related]
5. Validation of LOH profiles for assessing oral cancer risk.
Lingen MW; Szabo E
Cancer Prev Res (Phila); 2012 Sep; 5(9):1075-7. PubMed ID: 22911110
[TBL] [Abstract][Full Text] [Related]
6. Potential use of quantitative tissue phenotype to predict malignant risk for oral premalignant lesions.
Guillaud M; Zhang L; Poh C; Rosin MP; MacAulay C
Cancer Res; 2008 May; 68(9):3099-107. PubMed ID: 18451134
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity and immunoexpression of PTEN in oral epithelial dysplasia and squamous cell carcinoma.
Chaves FN; Bezerra TMM; Moraes DC; Costa SFDS; Silva PGB; Alves APNN; Costa FWG; Bernardes VF; Pereira KMA
Exp Mol Pathol; 2020 Feb; 112():104341. PubMed ID: 31730755
[TBL] [Abstract][Full Text] [Related]
8. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx.
Tabor MP; Braakhuis BJ; van der Wal JE; van Diest PJ; Leemans CR; Brakenhoff RH; Kummer JA
J Pathol; 2003 Mar; 199(3):354-60. PubMed ID: 12579537
[TBL] [Abstract][Full Text] [Related]
9. Increased allelic loss in toluidine blue-positive oral premalignant lesions.
Epstein JB; Zhang L; Poh C; Nakamura H; Berean K; Rosin M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):45-50. PubMed ID: 12539026
[TBL] [Abstract][Full Text] [Related]
10. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
[TBL] [Abstract][Full Text] [Related]
11. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection.
Zhang L; Poh CF; Lam WL; Epstein JB; Cheng X; Zhang X; Priddy R; Lovas J; Le ND; Rosin MP
Oral Oncol; 2001 Sep; 37(6):505-12. PubMed ID: 11435177
[TBL] [Abstract][Full Text] [Related]
12. Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome.
Zhang L; Williams M; Poh CF; Laronde D; Epstein JB; Durham S; Nakamura H; Berean K; Hovan A; Le ND; Hislop G; Priddy R; Hay J; Lam WL; Rosin MP
Cancer Res; 2005 Sep; 65(17):8017-21. PubMed ID: 16140975
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive molecular screening for oral precancer in Fanconi anemia patients.
Smetsers SE; Velleuer E; Dietrich R; Wu T; Brink A; Buijze M; Deeg DJ; Soulier J; Leemans CR; Braakhuis BJ; Brakenhoff RH
Cancer Prev Res (Phila); 2015 Nov; 8(11):1102-11. PubMed ID: 26276748
[TBL] [Abstract][Full Text] [Related]
14. Multiple aberrations of chromosome 3p detected in oral premalignant lesions.
Tsui IF; Rosin MP; Zhang L; Ng RT; Lam WL
Cancer Prev Res (Phila); 2008 Nov; 1(6):424-9. PubMed ID: 19138989
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of oral lichen planus. A premalignant lesion?
Zhang L; Michelsen C; Cheng X; Zeng T; Priddy R; Rosin MP
Am J Pathol; 1997 Aug; 151(2):323-7. PubMed ID: 9250145
[TBL] [Abstract][Full Text] [Related]
16. Molecular predictive factors for progression of high-grade preinvasive bronchial lesions.
Salaün M; Sesboüé R; Moreno-Swirc S; Metayer J; Bota S; Bourguignon J; Thiberville L
Am J Respir Crit Care Med; 2008 Apr; 177(8):880-6. PubMed ID: 17962638
[TBL] [Abstract][Full Text] [Related]
17. Unique FISH patterns associated with cancer progression of oral dysplasia.
Poh CF; Zhu Y; Chen E; Berean KW; Wu L; Zhang L; Rosin MP
J Dent Res; 2012 Jan; 91(1):52-7. PubMed ID: 21990607
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of p53 gene mutation and loss of heterozygosity of 3p, 9p and 17p in precancerous lesions of 29 lung cancer patients.
Nishisaka T; Takeshima Y; Inai K
Hiroshima J Med Sci; 2000 Jun; 49(2):109-16. PubMed ID: 10920577
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.
Cromwell I; Regier DA; Peacock SJ; Poh CF
Oncologist; 2016 Sep; 21(9):1099-106. PubMed ID: 27401887
[TBL] [Abstract][Full Text] [Related]
20. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia.
Kresty LA; Mallery SR; Knobloch TJ; Song H; Lloyd M; Casto BC; Weghorst CM
Cancer Res; 2002 Sep; 62(18):5295-300. PubMed ID: 12234999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
